1 How many patients (in the Trust) were initiated on ANTI TNF (originator and biosimilar) over the last 12 months?
2 How many patients (in the Trust) have been initiated on biosimilar adalimumab?
• and what is the split by brand in the last 12 months for the following products?
3 How many patients have been initiated on these products?
o guselkumab (Tremfya)
o risankizumab (Skyrizi)
o brodalumab (Kyntheum)
o ixekizumab (Taltz)
Download response ANTI TNF (originator and biosimilar). 200820